Philadelphia, Pennsylvania--(Newsfile Corp. - February 20, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Enphase Energy, Inc. (NASDAQ: ENPH) ("Enphase" or the "Company") on behalf of investors who purchased or otherwise acquired Enphase securities during the period from April 22, 2025 through October 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Enphase securities during the Class Period may, no later than Ap ...

Core Insights - PayPal Holdings, Inc. is under investigation for potential violations of federal securities laws following a significant earnings miss and subsequent stock price decline [1][5]. Analyst Expectations and Company Communications - On January 28, 2026, Rothschild & Co Redburn downgraded PayPal's price target from $70 to $50, which was followed by Morgan Stanley's similar reduction to $50 on January 29, citing slower checkout growth [2]. - Analysts had anticipated mid-single-digit revenue growth and higher earnings per share just before the earnings announcement on February 2, 2026 [2]. Earnings Results and Guidance - Actual results disclosed on February 3, 2026, showed revenue of $8.68 billion, falling short by $120 million (approximately 1.4%) from the $8.80 billion estimate [3]. - Adjusted earnings per share of $1.23 missed the consensus range of $1.30 to $1.33 by 5.4% to 7.5% [3]. - The company's forward guidance indicated a decline in 2026 transaction margin dollars and an adjusted earnings per share range projecting a low single-digit decline to a slight positive gain, significantly below market expectations [3]. Management Communication - During the third quarter 2025 earnings call on October 28, 2025, management did not indicate any forthcoming dramatic revisions to the company's outlook, raising questions about the information available to them prior to the earnings miss [4]. Stock Performance - Following the earnings announcement on February 3, 2026, PayPal shares dropped 19-20%, reaching approximately $42 and establishing a new 52-week low, with a reported increase in short interest as traders anticipated further declines [5].

Core Viewpoint - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% following the FDA's identification of deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the PDUFA action date [5]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with severe allergic reactions [5]. - The company is publicly traded on NASDAQ under the ticker symbol AQST [4]. Group 2: Recent Developments - The FDA has identified deficiencies in the New Drug Application for Anaphylm, which is an experimental sublingual film intended for the treatment of severe allergic reactions, including anaphylaxis [5]. - The deficiencies noted by the FDA currently prevent discussions regarding labeling and post-marketing requirements, which raises concerns about the likelihood of the application being approved by the January 31, 2026 PDUFA action date [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses due to the recent stock decline [4][5]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following a significant drop in its stock price due to disappointing clinical trial results for its lead drug candidate, ersodetug [4][5]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company listed on NASDAQ under the ticker RZLT [4]. - The company focuses on developing treatments for congenital hyperinsulinism, with ersodetug being its lead drug candidate [5]. Group 2: Recent Developments - On December 11, 2025, Rezolute's shares experienced a dramatic decline, falling from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% drop [6]. - The decline was triggered by the failure of the Phase 3 sunRIZE clinical trial for ersodetug, which did not meet its primary and key secondary endpoints, with the highest dose showing statistically insignificant reductions in hypoglycemia events compared to placebo [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Rezolute stock or options to discuss their legal rights [1]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Ralliant Corporation is under investigation for potential violations of federal securities laws following a significant financial impairment announcement that led to a sharp decline in its stock price [1][3]. Financial Performance - On February 4, 2026, Ralliant reported a fourth quarter and full year 2025 results, which included a non-cash goodwill impairment charge of $1.4 billion in the Test & Measurement segment, primarily due to revised expectations for the EA Elektro-Automatik business [3]. - Following this announcement, Ralliant's share price fell by $17.89, or approximately 31.8%, from $56.28 to $38.39 on the same day [3]. Legal Investigation - The law firm Kirby McInerney LLP is conducting an investigation on behalf of Ralliant investors to assess possible violations of federal securities laws and other unlawful business practices by the company or its senior management [1][4]. - As of now, no lawsuit has been filed, and the investigation is ongoing to determine if claims can be brought under federal securities laws [4].

Core Viewpoint - A class action lawsuit has been initiated against REGENXBIO Inc. due to alleged misrepresentations regarding its gene therapy product RGX-111, which has faced regulatory challenges following the discovery of a tumor in a trial participant [1][4]. Group 1: Lawsuit Details - The lawsuit, titled Andre Kuik v. REGENXBIO Inc., was filed in the United States District Court for the District of Maryland [1]. - The class action includes all individuals or entities that purchased REGENXBIO securities between February 9, 2022, and January 27, 2026 [1]. Group 2: Product and Trial Information - REGENXBIO's RGX-111 is a one-time gene therapy aimed at treating severe Mucopolysaccharidosis Type I, also known as Hurler syndrome [4]. - The company had previously made positive assertions regarding RGX-111's trial success based on favorable biomarker and safety data from an ongoing Phase I/II study [4]. Group 3: Stock Price Impact - Following the announcement of a clinical hold by the FDA due to the discovery of an intraventricular CNS tumor in a trial participant, REGENXBIO's stock price dropped from $13.41 to $11.01 per share, marking a decline of 17.8% in one day [5]. Group 4: Legal Representation - Levi & Korsinsky, LLP is representing the investors and has a history of securing significant compensation for shareholders in similar cases [6][7]. - Investors are encouraged to step forward before the April 14, 2026 deadline to be considered for lead plaintiff status [6].

Core Viewpoint - The article discusses a pending securities class action against Ardent Health, Inc. due to allegations of improper accounting practices that misled investors, leading to significant financial losses and a stock price collapse [2][8]. Group 1: Allegations and Legal Proceedings - The litigation centers on Ardent's alleged use of a rigid 180-day cliff for reserving uncollectible accounts, conflicting with prior claims of using detailed historical reviews for receivables valuation [2][8]. - The complaint suggests that Ardent delayed recognizing losses to maintain an artificial earnings quality profile during its initial public company phase [3][8]. - The lead plaintiff deadline for the class action is set for March 9, 2026, and investors who purchased shares between July 18, 2024, and November 12, 2025, are being advised to participate [4][5]. Group 2: Financial Impact and Stock Performance - Following the revelation of the accounting practices, Ardent experienced a 33% stock collapse, with a nearly 34% drop in stock price after disclosures on November 12, 2025 [2][8]. - The company reported a $54 million increase in professional liability reserves and a $42.6 million revenue reduction due to a new accounting method for estimating collectability of accounts receivable [8]. - The allegations also include claims that Ardent did not maintain sufficient professional malpractice liability insurance, contributing to the financial instability [8].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group PLC for allegedly making false and misleading statements regarding the success of its Phase 3 clinical trials for setrusumab, a treatment for Osteogenesis Imperfecta [1][2] Group 1: Lawsuit Details - The lawsuit includes all individuals and entities that purchased Mereo American Depositary Shares between June 5, 2023, and December 26, 2025 [1] - Investors have until April 6, 2026, to seek appointments as lead plaintiff [1][3] Group 2: Allegations Against Mereo - Investors allege that Mereo and certain executives expressed unwarranted confidence in the success of the ORBIT and COSMIC Phase 3 trials [2] - The company is accused of concealing adverse facts that contradicted their optimistic projections [2] Group 3: Trial Outcomes and Impact - On December 29, 2025, Mereo disclosed that neither the ORBIT nor COSMIC trials achieved statistical significance in reducing annualized fracture rates [3][7] - The share price plummeted from $2.31 to $0.29 in one trading session, representing a loss of over 87% of shareholder value [7]

Core Viewpoint - F5, Inc. has faced significant operational challenges following a security breach, leading to a substantial revision in its fiscal 2026 revenue guidance and a notable decline in stock price [5][6][9]. Financial Impact - F5's stock price fell from $343.17 on October 14, 2025, to $295.35 by October 16, 2025, marking a decline of 13.9%, and further dropped to $258.76 on October 28, 2025, reflecting an additional 10.9% decline, totaling approximately 25% over two disclosure events [1][9]. - The fiscal 2026 revenue guidance was dramatically revised from mid-single digits to a range of 0-4% growth, indicating a significant operational fallout from the undisclosed security breach [5][9]. Operational Challenges - The security incident allegedly resulted in reduced sales and renewals, elongated sales cycles as customers reevaluated their relationships, and increased remediation expenses [6][9]. - Customer renewal rates reportedly faced pressure following the disclosure of the security breach, impacting near-term revenue recognition [9]. Legal Context - A pending securities class action seeks to recover damages for investors who purchased F5 securities between October 28, 2024, and October 27, 2025, with a deadline for seeking lead plaintiff status set for February 17, 2026 [2].

Core Insights - ICON plc is under investigation for potential violations of federal securities laws related to its accounting practices and controls, initiated by the Audit Committee in late October 2025 [1] - Following the announcement of the internal investigation, ICON's stock price experienced a decline [1] Company Overview - ICON plc is publicly traded on NASDAQ under the ticker ICLR [1] - The ongoing internal investigation was prompted by concerns reported to the Audit Committee through Company management [1] Legal Context - Holzer & Holzer, LLC is investigating ICON's compliance with federal securities laws and is encouraging affected investors to reach out for legal consultation [2] - The firm specializes in representing shareholders and investors in litigation, including class action and derivative litigation [3]